Alternative Mechanism of Aspirin in Anti-Thrombotic Therapy: Inhibition of Thrombin Activatable Fibrinolysis Inhibitor

다국어 초록 (Multilingual Abstract)

The use of aspirin is widely recommended for the prevention of heart attacks owing to its ability to inhibit platelet activation by irreversibly blocking cyclooxygenase 1. However, aspirin also affects the fibrinolytic and hemostatic pathways by mechanisms that are not well understood, causing severe hemorrhagic complications. Here, we investigated the ability of aspirin and aspirin metabolites to inhibit thrombin-activatable fibrinolysis inhibitor (TAFI), the major inhibitor of plasma fibrinolysis. TAFI is activated via proteolytic cleavage by the thrombin-thrombomodulin complex to TAFIa, a carboxypeptidase B-like enzyme. TAFIa modulates fibrinolysis by removing the C-terminal arginine and lysine residues from partially degraded fibrin, which in turn inhibits the binding of plasminogen to fibrin clots. Aspirin and its major metabolites, salicylic acid, gentisic acid, and salicyluric acid, inhibit TAFIa carboxypeptidase activity. Salicyluric acid effectively blocks activation of TAFI by thrombin-thrombomodulin; however, salicylates do not inhibit carboxypeptidase N or pancreatic carboxypeptidase B. Aspirin and other salicylates accelerated the dissolution of fibrin clots and reduced thrombus formation in an in vitro model of fibrinolysis. Inhibition of TAFI represents a novel hemostatic mechanism that contributes to aspirin’s therapy-associated antithrombotic activity and hemorrhagic complications.

참고문헌 (Reference)

1 Antithrombotic Trialists’ Collaboration, 324 : 71-86, 2002

2 Barkin, R. L., 8 : 433-442, 2001

3 Steering Committee of the Physicians’ Health Study Research group, 321 : 129-135, 1989

4 Mangano, D. T., 347 : 1309-1317, 2002

5 Roth, G. J., 72 : 3073-3076, 1975

6 Burch, J. W., 61 : 34-39, 1978

7 Vane, J. R., 231 : 232-235, 1971

8 Baezinger, N., 16 : 967-974, 1979

9 Basinski, A., 20 : 1679-, 1992

10 Garabedian, H. D., 7 : 1213-1222, 1991

11 Bjornsson, T. D., 250 : 154-161, 1989

12 Undas, A., 98 : 2423-2431, 2001

13 Green, D., 13 : 394-398, 1983

14 de Gaetano, G., 35 : 3147-3150, 1986

15 Cattaneo, M., 61 : 353-361, 1983

16 Iacoviello, L., 229 : 39-44, 1992

17 Bounameaux, H., 40 : 161-170, 1985

18 Williams, S., 19 : 1666-1672, 1998

19 He, S., 53 : 24-29, 2009

20 Heylen, E., 17 : 2427-2450, 2011

21 Marx, P. F., 9 : 1165-1173, 2009

22 Redlitz, A., 96 : 2534-, 1995

23 Bajzar, L., 270 : 1477-, 1995

24 Lapi, F., 69 : 558-560, 2010

25 Meijers, J. C., 108 : 518-523, 2000

26 Watanabe, R., 104 : 1-6, 2001

27 Morange, P. E., 3 : 1503-1510, 2005

28 Meltzer, M. E., 116 : 113-121, 2010

29 Antovic, J., 7 : 557-560, 2001

30 Antovic, J. P., 64 : 745-751, 2004

31 Foley, J. H., 2011

32 Mikovic, D., 34 : 35-40, 2012

33 Nesheim, M., 3 (3): 33-39, 2003

34 Tosco, P., 4 : 939-945, 2009

35 Bjornsson, T. D., 250 : 154-161, 1989

36 Graham, G. G., 22 : 410-420, 1977

37 Second International Study of Infarct Survival Collaborative Group, 2 : 349-360, 1988

38 Insel, P. A., "Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 9th ed." McGraw-Hill 617-657, 1996

39 Raindford, K. D., "Aspirin and Related Drugs" CRC Press 97-137, 2004